Yi Xia

6PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 15, 2026
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

|Jun 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial.

|Mar 30, 2026
LM-101, an Anti-SIRPĪ± Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial.

Jun Cai, Baitian Zhao, Dongmei Ji

|Mar 28, 2026
Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Yuchen Zhang, Man Nie, Yi Cao

|Jun 09, 2025
Tumor-Associated Sympathetic Nerves Promote the Progression of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.

Silan Huang, Dexin Lei, Linbin Yang

|May 29, 2025
Cardiomyocyte-localized CCDC25 senses NET DNA to promote doxorubicin cardiotoxicity by activating autophagic flux.

Man Nie, Dexin Lei, Zhou Liu

Pageof 1

Frequent Collaborators

5 joint publications

Man Nie

4 joint publications

Qingqing Cai

2 joint publications

Panpan Liu

2 joint publications

Zhiming Li